- ￥100
- BPS Bioscience
- BPS-71273
- 美国
- 2025年07月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
100
- 供应商：
艾美捷科技
- 英文名：
ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat
- 规格：
2 vials
ADCP 生物测定效应细胞 FcγRIIa (H 变体) /NFAT 报告基因-Jurkat，ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat ，ADCP 生物测定效应细胞 FcγRIIa (H 变体) /NFAT 报告基因-Jurkat,ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat
ADCP 生物测定效应细胞 FcγRIIa (H 变体) /NFAT 报告基因-Jurkat-ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat
产品货号：BPS-71273
产品规格：2 vials
抗体依赖性细胞介导的吞噬作用是抗体药物开发的重要作用机制之一。FcγRIIa是参与ADCP过程的主要Fcγ受体。FcγRIIa在骨髓效应细胞(包括巨噬细胞和嗜中性粒细胞)中表达，其在这些效应细胞的活化中起作用。几项临床研究已经研究了FcγRIIa多态性(R131H)与对igg1亚类单克隆抗体(mab)如利妥昔单抗的反应的相关性。已经开发了fc-mab中的工程化氨基酸取代以增强巨噬细胞对mab介导的肿瘤细胞的吞噬作用。
表征抗体的Fc效应功能。
ADCP 生物测定效应细胞 FcγRIIa (H 变体) /NFAT 报告基因-Jurkat-ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat 收到后立即储存在液氮中。
点击：ADCP 生物测定效应细胞 FcγRIIa (H 变体) /NFAT 报告基因-Jurkat-ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat 更多BPS biosciencer产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Structural analog of Cyclotheonellazole A, and synthetic method therefor and application method thereof.
Therapeutic Potential of Dimethyl Fumarate for the Treatment of High-Fat/High-Sucrose Diet-Induced Obesity.
Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission
either from purified antibodies or from crude cell media supernatants are captured by the protein A and are used as the ligand. Soluble forms of FcγRs are injected at different concentrations and are used as the analyte. This setup allows the definition of the kinetic
Analysis of RB Action in DNA Damage Checkpoint Response
checkpoint response: (1) transcriptional repression of E2F-regulated genes (cyclin A reporter assay); (2) induction of cell cycle arrest (Brd-U incorporation assay); and (3) inhibition of DNA double-strand break accumulation (phosphorylated-histone H2A.X
Psychoneuroimmunology and Natural Killer Cells: The Chromium Release Whole Blood Assay
) release bioassay designed to measure the target cell killing capacity of NK cells (NKCC). Key features of the cytotoxicity assay are that it is done with whole blood and that numbers of effector cells are determined for each sample by flow cytometry
技术资料暂无技术资料 索取技术资料
